Press Enter to search · ESC to close

Macro

FDA Adds Rare Blindness Risk Warning to GLP-1 Drugs Including Ozempic, Zepbound

The U.S. Food and Drug Administration has required makers of major GLP-1 drugs including Ozempic and Zepbound to add a warning label for non-arteritic anterior ischemic optic neuropathy (NAION), a rare eye condition that can cause permanent vision loss. FDA data show about 6 NAION cases per 100,000 people taking the drugs each year.

Share

Related News

Cointime share card
Long-press the image to save or share
Pitch us Community Feedback